Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,532,768
  • Shares Outstanding, K 211,010
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.80
  • Price/Sales 5.98
  • Price/Cash Flow 12.84
  • Price/Book 5.23

Price Performance

See More
Period Period Low Period High Performance
1-Month
283.24 +23.03%
on 06/18/18
367.89 -5.28%
on 07/06/18
+41.57 (+13.54%)
since 06/13/18
3-Month
249.17 +39.86%
on 04/24/18
367.89 -5.28%
on 07/06/18
+83.09 (+31.31%)
since 04/13/18
52-Week
249.17 +39.86%
on 04/24/18
370.57 -5.96%
on 01/26/18
+70.12 (+25.19%)
since 07/13/17

Most Recent Stories

More News
Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

MPC : 71.74 (+1.74%)
AVGO : 202.46 (-3.58%)
LLY : 89.71 (+0.90%)
PEP : 112.69 (+1.04%)
MMM : 201.18 (+0.93%)
BIIB : 348.48 (+0.24%)
Dopamine and the Weather, Part 2

How technology changes human behavior and social rules, but not human nature and genetics???yet.

NVDA : 249.32 (-0.76%)
CRSP : 65.71 (+1.01%)
BLUE : 180.60 (+0.17%)
ACAD : 17.46 (-1.69%)
BIIB : 348.48 (+0.24%)
AbbVie's Imbruvica Fails in Phase III Blood Cancer Study

AbbVie's (ABBV) Imbruvica fails to meet the primary endpoint in a phase III study evaluating the drug in patients with DLBCL, a rare blood cancer, who have received no prior treatment.

JNJ : 125.93 (-1.43%)
ABBV : 96.63 (+1.07%)
RHHBY : 29.0500 (+1.15%)
BIIB : 348.48 (+0.24%)
Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

CELG : 85.69 (+0.11%)
IDRA : 1.01 (-4.72%)
AXON : 2.67 (+6.80%)
XLRN : 45.86 (-2.65%)
BIIB : 348.48 (+0.24%)
Biogen Inc (BIIB) Crosses Pivot Point Support at $347.56

Shares of Biogen Inc (NASDAQ:BIIB) opened today below their pivot of $353.95 and have already reached the first level of support at $347.56. Should the shares continue to fall, the support pivots of $341.11...

BIIB : 348.48 (+0.24%)
CTI BioPharma Falls After Failure of Pivotal Lymphoma Study

CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.

CELG : 85.69 (+0.11%)
CTIC : 4.13 (-3.73%)
RHHBY : 29.0500 (+1.15%)
BIIB : 348.48 (+0.24%)
Today's Research Reports on Stocks to Watch: Biogen and Amgen

NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Biogen shares skyrocketed after announcing positive results in an Alzheimer's drug study. Shares of Amgen also moved north as Wall Street's celebration of Biogen's...

AMGN : 195.91 (+0.94%)
BIIB : 348.48 (+0.24%)
Biotech ETFs Surge on Biogen's Positive Drug Trial Result

Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.

PBE : 59.14 (-0.08%)
CELG : 85.69 (+0.11%)
IBB : 118.35 (+0.17%)
FBT : 150.77 (+0.03%)
BBH : 128.69 (+0.32%)
GILD : 77.38 (-0.28%)
AMGN : 195.91 (+0.94%)
BIIB : 348.48 (+0.24%)
Stock Market News For Jul 9, 2018

Wall Street continues its winning streak for the second straight session with all three major stock indexes closing in positive territory on Friday

MSFT : 105.43 (+1.19%)
AAPL : 191.33 (+0.16%)
FB : 207.32 (+0.19%)
BIIB : 348.48 (+0.24%)
Biotech ETFs Surge on Biogen's Positive Drug Trial Result

Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.

PBE : 59.14 (-0.08%)
CELG : 85.69 (+0.11%)
IBB : 118.35 (+0.17%)
FBT : 150.77 (+0.03%)
BBH : 128.69 (+0.32%)
GILD : 77.38 (-0.28%)
AMGN : 195.91 (+0.94%)
BIIB : 348.48 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 355.69
1st Resistance Point 352.08
Last Price 348.48
1st Support Level 344.46
2nd Support Level 340.45

See More

52-Week High 370.57
Last Price 348.48
Fibonacci 61.8% 324.20
Fibonacci 50% 309.87
Fibonacci 38.2% 295.54
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar